Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment

Inclusion Criteria: * Patients with NVAF and SRI, or patients with NVAF and Normal/MiRI. Exclusion Criteria: * Patients who are on hemodialysis or patients who may start hemodialysis before the follow-up assessment * Patients who are at a significantly high risk for bleeding * Patients who are receiving treatment with any anticoagulant drugs excluding warfarin, rivaroxaban, and dabigatran * Patients who have evidence of hepatic function test abnormalities